GOLD leaders say COPD is diagnosed too late and its smoking-only image is outdated, and the 2027 report puts rehab and non-drug care up front.
|Articles|June 6, 2012
Supreme Court: Decision Nears on 'Obamacare'
Advertisement
The Supreme Court is expected to announce its ruling on the Affordable Care Act (ACA) this month, and with the countdown started speculation about the impact of that decision is heating up on both sides of the "Obamacare" debate.
And both sides predict disaster for doctors -- massive disruption if the law is struck down -- or if it is upheld.
Read the full story:
Source: MedPage Today
Advertisement
Related to this article
This week in health equity and access: Medicaid cuts; mailed FIT outreach; EEOC pregnancy rules; GLP-1 Bridge access; and 2027 policy shifts.
Experts say no inhaler suits every patient with chronic obstructive pulmonary disease, and technique can fade within 30 days without retraining.
Experts say COPD care should aim for disease stability, with advanced therapy a routine next step, not a last resort, for patients who fall short.
Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.
Hepatitis B functional cure with bepirovirsen held in 90% to 92% of responders 48 weeks after stopping all therapy, per data at The Liver Meeting 2026.
Most patients with CLL/SLL who discontinued a first-line BTK inhibitor did not start second-line therapy, and older age was linked to worse outcomes.
Resmetirom real-world data at The Liver Meeting 2026 show 12-month gains in liver stiffness, fat, and enzymes among patients with MASH in 3 US data sets.
Advertisement
Advertisement
Trending on AJMC
1
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
2
Medicaid Cuts and Caregiving in Congress: Andy Kim
3
GLP-1 RAs Improve MASLD, MASH Markers, but Long-Term Benefits Unclear
4
Health Equity & Access Weekly Roundup: November 6, 2026
5